Search clinical trials for: B-Cell Lymphoma

Total 10669 results

Children's Oncology Group
National Cancer Institute (NCI)

Completed

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Acute Lymphoblastic Leukemia | B-Cell Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia | Childhood Burkitt Lymphoma | Childhood Neoplasm

United States, Puerto Rico
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
Regeneron Pharmaceuticals

Available

A Compassionate Use (CU) Program of Odronextamab

Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | B-Cell Non-Hodgkin Lymphoma (NHL) | High-Grade B-Cell Lymphoma (HGBCL)
Mayo Clinic

Completed

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

Hodgkin Lymphoma | B-cell Non Hodgkin Lymphoma | Monoclonal B-Cell Lymphocytosis | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of California... and other collaborators

Active, not recruiting

Communication Skills Intervention to Promote Transition Into Survivorship

Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
Epizyme, Inc.

Completed

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditions

United States
Novartis Pharmaceuticals

Completed

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

Diffuse Large B-cell Lymphoma

United States
University of Maryland, Baltimore
Gilead Sciences; University of Miami Sylvester Comprehensive Cancer Center

Active, not recruiting

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Follicular Lymphoma | B-cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Transformed Lymphoma | Indolent Lymphoma

United States
Fox Chase Cancer Center

Active, not recruiting

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

Diffuse Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Leukemia

United States
Celgene

Completed

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (ROBUST)

Lymphoma, Large B-Cell, Diffuse

United States, Australia, Belgium, Canada, China, Czechia, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Switzerland, Taiwan, Turkey
University of Pennsylvania

Completed

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Refractory Aggressive Non-Hodgkin Lymphoma

United States
Incyte Corporation

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Xynomic Pharmaceuticals, Inc.

Active, not recruiting

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United States
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Lymphoma, Non-Hodgkin | B-cell Lymphoma | Multiple Myeloma | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, B-cell Marginal Zone

United States, France, Poland, Italy
Epizyme, Inc.

Completed

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Solid Tumor | Mesothelioma | Rhabdoid Tumor | Hematologic Malignancy | Advanced Malignancies | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | All Malignancies | Epithelioid Sarcoma (ES)

Spain, United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Amgen

Active, not recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma | Pre B-Cell Acute Lymphoblastic Leukaemia

United States
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Diffuse Large B-cell Lymphoma

Netherlands, United Kingdom, Italy, Czechia
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University College London Hospitals

Completed

CAR T Cell Therapy Related Cardiovascular Outcomes (CARTCO)

Cardiovascular Diseases | Diffuse Large B Cell Lymphoma | Cardiotoxicity | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | B-cell Lymphoma Refractory | Cardiovascular Complication | B-cell Lymphoma Recurrent

United Kingdom
Pack Health
Novartis; Ohio State University Comprehensive Cancer Center

Terminated

Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

Lymphoma, Large B-Cell, Diffuse

United States
Duke University
National Cancer Institute (NCI)

Completed

Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Burkitt Lymphoma | Retinoblastoma | Diffuse Large B-cell Lymphoma

Tanzania
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
University of Cologne
Novartis

Terminated

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019)

Non Hodgkin Lymphoma

Germany
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
University College, London

Completed

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation (COBALT)

Diffuse Large B-Cell Lymphoma

United Kingdom
National Cancer Institute (NCI)

Completed

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Burkitt Lymphoma | Plasmablastic Lymphoma | Diffuse Large B-cell Lymphoma, c-MYC Positive

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients (HO902DLBCL)

NHL

Netherlands
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
Seoul National University Hospital

Completed

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell

Korea, Republic of
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Genentech, Inc.

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Multiple Myeloma | Non-Hodgkin Lymphoma | B-Cell Lymphoma

United States, Korea, Republic of
The First Affiliated Hospital of Soochow University

Enrolling by invitation

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

China
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

China

Search clinical trials for: B-Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations